Will echelon be doing another report? It would appear their valuation needs some major adjusting. The company has always traded at a fairly high revenue multiple maybe too high, none the less.
Revenue in Q3 of 2020 has shown a 5900% increase compared to Q3 of 2019.
Forward looking a conservative 3000% increase in annual revenue( roughly 8 million cdn).
The company showing loss may put a sting in this although it is largely in part due to the revaluation of warrants.
On the business end they are still operating at loss, one which can surely be scaled out of. -30% although not cash flow positive it is leaps and bounds ahead of many biotech peers.
When compared to many biotech peers it is clear Stagezero life sciences, is extremely undervalued solely based on fundamentals.
This obviously does not factor in the price tag that will be put on the emerging cancer diagnostic panel Aristotle*